DE69916581D1 - Eine universelle immunmodulatorische cytokin-expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen - Google Patents
Eine universelle immunmodulatorische cytokin-expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungenInfo
- Publication number
- DE69916581D1 DE69916581D1 DE69916581T DE69916581T DE69916581D1 DE 69916581 D1 DE69916581 D1 DE 69916581D1 DE 69916581 T DE69916581 T DE 69916581T DE 69916581 T DE69916581 T DE 69916581T DE 69916581 D1 DE69916581 D1 DE 69916581D1
- Authority
- DE
- Germany
- Prior art keywords
- cell line
- cytokin
- modulatory
- waiting
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000000981 bystander Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7340598P | 1998-02-02 | 1998-02-02 | |
US73405P | 1998-02-02 | ||
PCT/US1999/002253 WO1999038954A1 (en) | 1998-02-02 | 1999-02-02 | A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69916581D1 true DE69916581D1 (de) | 2004-05-27 |
DE69916581T2 DE69916581T2 (de) | 2004-09-16 |
Family
ID=22113512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69916581T Expired - Lifetime DE69916581T2 (de) | 1998-02-02 | 1999-02-02 | Eine universelle immunmodulatorische cytokin-expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen |
Country Status (10)
Country | Link |
---|---|
US (5) | US6464973B1 (de) |
EP (1) | EP1053301B1 (de) |
JP (1) | JP4303887B2 (de) |
KR (1) | KR20010074426A (de) |
AT (1) | ATE264911T1 (de) |
AU (1) | AU741602B2 (de) |
CA (1) | CA2318372C (de) |
DE (1) | DE69916581T2 (de) |
ES (1) | ES2218994T3 (de) |
WO (1) | WO1999038954A1 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU741602B2 (en) * | 1998-02-02 | 2001-12-06 | Johns Hopkins University School Of Medicine, The | A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
US7638326B2 (en) | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
WO2003057171A2 (en) * | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
US7745140B2 (en) * | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
EP1374893A1 (de) * | 2002-06-17 | 2004-01-02 | NovImmune S.A. | Impfung mit Immuno-isolierten Zellen die einen Immunomodulator Produzieren |
US7740871B2 (en) | 2002-09-19 | 2010-06-22 | Johns Hopkins University School Of Medicine | Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine |
US7176022B2 (en) | 2002-12-20 | 2007-02-13 | Cell Genesys, Inc. | Directly injectable formulations which provide enhanced cryoprotection of cell products |
US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
EP1636360A4 (de) * | 2003-06-03 | 2006-11-08 | Cell Genesys Inc | Zusammensetzungen und verfahren zur verstärkten expression rekombinanter polypeptide von einem vektor unter verwendung einer peptidspaltstelle |
US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
SI1523991T1 (sl) * | 2003-10-18 | 2014-07-31 | Alind & Kraja Sha | Cepivo proti raku |
EP1765988B1 (de) | 2004-05-27 | 2017-09-20 | The Trustees of The University of Pennsylvania | Neue künstliches antigen präsentierende zellen und verwendungen dafür |
US20060062764A1 (en) * | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
US20060057127A1 (en) * | 2004-09-10 | 2006-03-16 | Pocheng Liu | Cytokine-expressing cellular vaccines for treatment of prostate cancer |
JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ctla−4抗体の限局性分泌のための方法および組成物 |
US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
US20090311226A1 (en) * | 2006-05-22 | 2009-12-17 | The John Hopkins University | Composition and method for treating esophageal dysplasia |
US7901902B2 (en) | 2006-07-27 | 2011-03-08 | Biosante Pharmaceuticals, Inc. | Methods and compositions for identifying a cellular immune response against prostate cancer |
US7939271B2 (en) * | 2007-03-02 | 2011-05-10 | Biosante Pharmaceuticals, Inc. | Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer |
WO2008124102A2 (en) * | 2007-04-06 | 2008-10-16 | Cell Genesys Inc. | Ara-c in combination with a cytokine-secreting cell and use thereof |
WO2009014708A2 (en) * | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
WO2009032256A2 (en) * | 2007-08-30 | 2009-03-12 | Cell Genesys, Inc. | Apc activators in combination with a cytokine-secreting cell and methods of use thereof |
WO2009085237A2 (en) * | 2007-12-21 | 2009-07-09 | Cell Genesys, Inc. | Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer |
CN102056538B (zh) * | 2008-06-06 | 2014-10-15 | 柯惠有限合伙公司 | 用于在换气系统中确定患者努力及/或呼吸参数的系统及方法 |
US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
EP2364152A4 (de) * | 2008-11-03 | 2013-02-13 | Univ Johns Hopkins | Verfahren zur herstellung und verwendung von markinfiltrierenden lymphozyten (mils) |
WO2011097477A1 (en) | 2010-02-04 | 2011-08-11 | The Trustees Of The University Of Pennsylvania | Icos critically regulates the expansion and function of inflammatory human th17 cells |
BR112012027745A2 (pt) | 2010-04-27 | 2017-01-10 | Univ Johns Hopkins | método e composição imunogênica para tratamento de neoplásia |
JP5849710B2 (ja) * | 2011-02-03 | 2016-02-03 | セントラル硝子株式会社 | β−フルオロアルコール類の製造方法 |
IN2014MN02492A (de) | 2012-06-08 | 2015-07-17 | Aduro Biotech | |
EP2931738B1 (de) | 2012-12-13 | 2019-02-06 | Aduro Biotech, Inc. | Zusammensetzungen mit cyclischen purin-dinukleotiden mit definierter stereochemie sowie verfahren zu deren herstellung und verwendung |
US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
SG11201508165VA (en) | 2013-04-29 | 2015-11-27 | Sloan Kettering Inst Cancer | Compositions and methods for altering second messenger signaling |
WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
MX354057B (es) | 2013-05-18 | 2018-02-09 | The Regents Of The Univ Of California Star | Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón". |
WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
SG11201609118RA (en) | 2014-05-15 | 2016-11-29 | Univ Singapore | Modified natural killer cells and uses thereof |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
EP3352783B1 (de) | 2015-09-25 | 2021-08-25 | MaxiVAX SA | Impfstoff, der einen immunomodulator produzierende immunoisolierte zellen enthält |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
EP3600356A4 (de) | 2017-03-27 | 2020-12-23 | National University of Singapore | Verkürzte chimäre nkg2d-rezeptoren und verwendungen davon in der immuntherapie mit natürlichen killerzellen |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
MX2021010670A (es) | 2019-03-05 | 2021-11-12 | Nkarta Inc | Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia. |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744347A (en) | 1987-01-16 | 1998-04-28 | Ohio University Edison Biotechnology Institute | Yolk sac stem cells and their uses |
US5705732A (en) | 1989-06-12 | 1998-01-06 | Oklahoma Medical Research Foundation | Universal donor cells |
US5574205A (en) * | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
JPH04501510A (ja) * | 1989-07-25 | 1992-03-19 | セル ジェネシス,インコーポレイティド | 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え |
US5681562A (en) * | 1991-06-25 | 1997-10-28 | Sidney Kimmel Cancer Center | Lymphokine gene therapy of cancer |
US5674486A (en) * | 1991-06-25 | 1997-10-07 | San Diego Regional Cancer Center | Cancer immunotherapy with carrier cells |
US5637483A (en) * | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
CA2121487A1 (en) | 1991-10-21 | 1993-04-29 | Stephen A. Sherwin | Combined cellular and immunosuppresive therapies |
ATE188125T1 (de) * | 1991-10-25 | 2000-01-15 | Sidney Kimmel Cancer Ct | Lymphokine gentherapie bei krebs in kombination mit tumorantigenen |
FR2683725B1 (fr) * | 1991-11-15 | 1995-07-07 | Pasteur Institut | Composition cellulaire pour le traitement des organismes humains ou animaux. |
JPH08504095A (ja) * | 1992-09-18 | 1996-05-07 | カンジ,インコーポレイテッド | 腫瘍抑制遺伝子を有するレトロウイルスベクターによる遺伝子療法 |
CA2178902A1 (en) * | 1993-12-14 | 1995-06-22 | Drew Pardoll | Controlled release of pharmaceutically active substances for immunotherapy |
AU5634696A (en) * | 1995-04-28 | 1996-11-18 | Genetic Therapy, Inc. | Treatment of tumors with cells expressing interferons, tumor necrosis factors, or other cytokines |
DE19541450C2 (de) * | 1995-11-07 | 1997-10-02 | Gsf Forschungszentrum Umwelt | Genkonstrukt und dessen Verwendung |
DE19608751B4 (de) * | 1996-03-06 | 2006-05-18 | Medigene Ag | Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen |
AU741602B2 (en) * | 1998-02-02 | 2001-12-06 | Johns Hopkins University School Of Medicine, The | A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
-
1999
- 1999-02-02 AU AU25764/99A patent/AU741602B2/en not_active Expired
- 1999-02-02 JP JP2000529415A patent/JP4303887B2/ja not_active Expired - Lifetime
- 1999-02-02 KR KR1020007008382A patent/KR20010074426A/ko not_active Application Discontinuation
- 1999-02-02 CA CA002318372A patent/CA2318372C/en not_active Expired - Lifetime
- 1999-02-02 US US09/241,939 patent/US6464973B1/en not_active Expired - Lifetime
- 1999-02-02 ES ES99905651T patent/ES2218994T3/es not_active Expired - Lifetime
- 1999-02-02 AT AT99905651T patent/ATE264911T1/de not_active IP Right Cessation
- 1999-02-02 DE DE69916581T patent/DE69916581T2/de not_active Expired - Lifetime
- 1999-02-02 WO PCT/US1999/002253 patent/WO1999038954A1/en active IP Right Grant
- 1999-02-02 EP EP99905651A patent/EP1053301B1/de not_active Expired - Lifetime
-
2001
- 2001-11-16 US US09/992,443 patent/US20020037282A1/en not_active Abandoned
-
2006
- 2006-02-23 US US11/361,832 patent/US7390483B2/en not_active Expired - Fee Related
-
2008
- 2008-06-13 US US12/139,001 patent/US8012469B2/en not_active Expired - Fee Related
-
2011
- 2011-07-29 US US13/194,105 patent/US20110287058A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2576499A (en) | 1999-08-16 |
JP2002501741A (ja) | 2002-01-22 |
CA2318372A1 (en) | 1999-08-05 |
DE69916581T2 (de) | 2004-09-16 |
US7390483B2 (en) | 2008-06-24 |
US20020037282A1 (en) | 2002-03-28 |
JP4303887B2 (ja) | 2009-07-29 |
US20060140922A1 (en) | 2006-06-29 |
US6464973B1 (en) | 2002-10-15 |
US8012469B2 (en) | 2011-09-06 |
EP1053301B1 (de) | 2004-04-21 |
ATE264911T1 (de) | 2004-05-15 |
CA2318372C (en) | 2008-08-19 |
AU741602B2 (en) | 2001-12-06 |
ES2218994T3 (es) | 2004-11-16 |
WO1999038954A1 (en) | 1999-08-05 |
EP1053301A1 (de) | 2000-11-22 |
US20080260758A1 (en) | 2008-10-23 |
US20110287058A1 (en) | 2011-11-24 |
KR20010074426A (ko) | 2001-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69916581D1 (de) | Eine universelle immunmodulatorische cytokin-expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen | |
ATE481108T1 (de) | Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen | |
AP2001002225A0 (en) | 1-heterocycle substituted diarylamines. | |
AU1593001A (en) | Recombinant gelatin in vaccines | |
DK0939767T3 (da) | Procin faktor VIII og hybrider deraf | |
PT1157041E (pt) | Anticorpos para terapia e diagnostico de cancro | |
TR200100056T2 (tr) | Nörotrofik faktörler | |
CY1105963T1 (el) | Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης | |
DE69023896T2 (de) | Zementhilfsmittel, dessen herstellung sowie zementzusammensetzung. | |
PT76420A (de) | Neue quartaere 6,11-dihydro-dibenzo-<b,e>-thiepin-11-n-lakyl-norscopinether und verfahren zu deren herstellung | |
GR1003350B (el) | Νεες ενωσεις | |
DE3585953D1 (de) | Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine. | |
DE69717259T2 (de) | Dienkautschuk, verfahren zur herstellung des kautschuks und kautschukzusammensetzung die diesen enthält | |
HK1040983A1 (en) | Quinones for treatment of diseases. | |
DE59712319D1 (de) | Genfallen-konstrukt zur identifizierung und isolierung von genen | |
DK0704501T3 (da) | Højtransparente, røde jernoxidpigmenter, fremgangsmåde til deres fremstilling og anvendelse | |
AU1337783A (en) | New fibrionoltic enzymes | |
AR001014A1 (es) | Una molecula de dna aislada que codifica daunorubicina 14-hidroxilasa, dicha daunorubicina 14-hidroxilasa, procedimiento para producir dicho dna,vector que comprende dicho dna, celula huesped que contiene dicho vector, procedimiento para producir doxorubicina mediante dicha celula | |
IL139604A0 (en) | Novel peptides | |
DK0939769T3 (da) | Vertebrat-Smoothened-proteiner | |
DE59707813D1 (de) | Rezeptorbindungsassay, für den rezeptorbindungsassay geeigneter rekombinanter fusionsrezeptor, vektor zu dessen herstellung sowie reagenziensatz für die durchführung des rezeptorbindungsassays | |
PE20399A1 (es) | Muteina ob | |
DE3671603D1 (de) | Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose. | |
ITMI932171A1 (it) | Procedimento per l'estrazione di colori naturali mediante bentonite | |
DE69615537D1 (en) | Helicobacter pylori antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |